Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is believed to promote ammonia detoxification in the liver and brain.
## Primary Indications
Treatment of latent and manifest hepatic encephalopathy.
## Adult Dosing
* **Hepatic Encephalopathy (Latent/Manifest):** Typically 3 grams (equivalent to 1 sachet of 3g powder for oral solution or 1 ampoule of 5g/10mL solution) administered orally, three times daily. Maximum recommended dose is 18 grams per day. For intravenous administration, typically 5 grams to 10 grams infused over 30-60 minutes, up to twice daily. Specific infusion rates and total daily doses for IV administration may vary based on patient condition and local protocol.
## Pediatric Dosing
* Dosing in pediatric patients is not specifically established due to limited data. Dosing should be individualized and carefully considered by a qualified healthcare provider.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is metabolized by the liver and its components are natural amino acids. However, caution may be warranted in severe hepatic impairment.
## Contraindications
* Hypersensitivity to l-ornithine l-aspartate or any component of the formulation.
* Severe renal insufficiency (creatinine > 3 mg/dL) is a relative contraindication due to potential accumulation of amino acids.
## Adverse Effects
* Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain) are most common.
* Rarely, skin rash or allergic reactions may occur.
## Key Drug Interactions
* No significant drug interactions are widely reported.
## Monitoring
* Monitor for signs and symptoms of hepatic encephalopathy.
* Monitor electrolyte balance, especially in patients with gastrointestinal losses.
## Clinical Pearls
* Oral administration is preferred for chronic management. Intravenous administration is typically reserved for more severe cases or when oral intake is not possible.
* The effectiveness is primarily seen in patients with impaired liver function.
* The product is typically available as granules for oral solution or as an injection solution.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the current Prescribing Information or Summary of Product Characteristics for complete drug information, including specific indications, contraindications, warnings, precautions, adverse reactions, and drug interactions, as these may vary by region and have been updated since this summary was generated. Always verify with authoritative sources before making clinical decisions.
